TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28970513

Group type: EXPERIMENTAL
Intervention: Higher cholesterol efflux/apoA-I quartile
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux/apoA-I ratio
Number of subjects: 462
Study: 28970956

Group type: EXPERIMENTAL
Intervention: R-Y reconstruction using two circular staplers
Number of subjects: 118

Group type: COMPARATOR
Intervention: B-I reconstruction
Number of subjects: 118
Study: 28971097

Group type: EXPERIMENTAL
Intervention: Iron- and zinc-biofortified pearl millet (FeZnPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pearl millet (CPM)
Number of subjects: 0
Study: 28971223

Group type: EXPERIMENTAL
Intervention: Index offspring (offspring of women with type 1 diabetes)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control offspring
Number of subjects: 581
Study: 28971850

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28971851

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28971861

Group type: EXPERIMENTAL
Intervention: Micafungin; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 28971900

Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily
Number of subjects: 72
Study: 28972002

Group type: EXPERIMENTAL
Intervention: Cardiac myosin-binding protein C (cMyC)
Number of subjects: 1954

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1954

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1954
Study: 28972011

Group type: EXPERIMENTAL
Intervention: Oral leniolisib (CDZ173)
Number of subjects: 6
Study: 28972913

Group type: EXPERIMENTAL
Intervention: WTCHR group
Number of subjects: 402

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 402
Study: 28973026

Group type: EXPERIMENTAL
Intervention: Low serum phosphate
Number of subjects: 3226

Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients older than 65 years
Number of subjects: 3226

Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients on dialysis more than one year
Number of subjects: 3226

Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients with serum albumin lower than 3.9 g/dL
Number of subjects: 3226
Study: 28973091

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement with the SAPIEN 3 valve
Number of subjects: 1661
Study: 28973164

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoglycemic Intravenous Glucose Infusion (IIGI)
Number of subjects: 12
Study: 28973223

Group type: EXPERIMENTAL
Intervention: Sleep restriction (5.6 hours sleep/24 hours) with circadian disruption (recurring 28-hour 'day' in dim light) for 3 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian disruption
Number of subjects: 10
Study: 28973403

Group type: EXPERIMENTAL
Intervention: Rilotumumab monotherapy (10 or 20 mg/kg IV every 2 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rilotumumab in combination with cisplatin (80 mg/m2 on Day 1) and capecitabine (1000 mg/m2 twice daily on Days 1-14 of every 21-day cycle)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adverse events related to any treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities (DLTs)
Number of subjects: 21
Study: 28973520

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR), n=321
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR), n=313
Number of subjects: 2795

Group type: COMPARATOR
Intervention: TAVR vs medical treatment, n=165
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Continued access observational studies (TAVR), n=1996
Number of subjects: 2795
Study: 28973622

Group type: EXPERIMENTAL
Intervention: 10 mg/d of biotin supplementation for 7 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nonbiotinylated assays (14 assays)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Biotinylated competitive immunoassays
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Biotinylated sandwich immunoassays
Number of subjects: 6
Study: 28974059

Group type: EXPERIMENTAL
Intervention: Augmented pulse pressure variation (PPV12) induced by 2-min ventilation with a tidal volume (V T ) of 12 ml kg -1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard pulse pressure variation (PPV8) with a tidal volume of 8 ml kg -1
Number of subjects: 38
Study: 28974067

Group type: EXPERIMENTAL
Intervention: High inspiratory oxygen fraction (FIO2)
Number of subjects: 73922

Group type: COMPARATOR
Intervention: Low inspiratory oxygen fraction (FIO2)
Number of subjects: 73922
Study: 28974209

Group type: EXPERIMENTAL
Intervention: Automated voice messages about contraception sent to mobile phones (11 messages over 4 months)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Usual clinic care including contraceptive counselling and call centre access
Number of subjects: 960
Study: 28974224

Group type: EXPERIMENTAL
Intervention: Baseline externalizing behavior T-score (higher externalizing behavior) among boys
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Baseline externalizing behavior T-score (higher externalizing behavior) among girls
Number of subjects: 524
Study: 28974230

Group type: EXPERIMENTAL
Intervention: Vitrified embryos
Number of subjects: 286

Group type: COMPARATOR
Intervention: Slow frozen embryos
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Intact embryos
Number of subjects: 286

Group type: COMPARATOR
Intervention: Not intact embryos
Number of subjects: 286
Study: 28974464

Group type: EXPERIMENTAL
Intervention: Caregivers of any kind
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Caregivers of plants
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Caregivers of persons
Number of subjects: 107
Study: 28974483

Group type: EXPERIMENTAL
Intervention: SmokefreeMOM (automated smoking cessation text-messaging program)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: SmokefreeMOM
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (quitline referral)
Number of subjects: 99
Study: 28974486

Group type: EXPERIMENTAL
Intervention: Exercise training plus beetroot (EX+BR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise training plus placebo (EX+PL)
Number of subjects: 30
Study: 28974506

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin + consolidative stem cell transplant (SCT)
Number of subjects: 58
Study: 28975039

Group type: EXPERIMENTAL
Intervention: Creative music therapy (CMT), approximately 20 minutes duration, three times per week, delivered by a trained music therapist singing in lullaby style, adjusted to the infant's rhythm and affect.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care with CMT.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard neonatal intensive care.
Number of subjects: 60
Study: 28975040

Group type: EXPERIMENTAL
Intervention: Small volume plasma exchange (SVPE)
Number of subjects: 20
Study: 28975084

Group type: EXPERIMENTAL
Intervention: Cisplatin-Etoposide (CE)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Ifosfamide + Etoposide + Epirubicin (IVE)
Number of subjects: 346
Study: 28976050

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with mouth constantly open
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with lip retraction
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with alternating direct and indirect imaging
Number of subjects: 70
Study: 28976556

Group type: EXPERIMENTAL
Intervention: SAR260301 (100 mg to 440 mg once daily)
Number of subjects: 21
Study: 28976817

Group type: EXPERIMENTAL
Intervention: Lenti-D gene therapy (autologous CD34+ cells transduced with elivaldogene tavalentivec)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lenti-D gene therapy
Number of subjects: 17
Study: 28977361

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Medical treatment (unoperated)
Number of subjects: 442
Study: 28977548

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Postero-lateral thoracotomy (PLT)
Number of subjects: 31
Study: 28977630

Group type: EXPERIMENTAL
Intervention: Limited cutaneous systemic sclerosis (lcSSc)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ACA)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Worsening of dyspnoea
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Higher HAQ-DI
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Active finger ulceration
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Urinary incontinence (UI)
Number of subjects: 334
Study: 28978139

Group type: EXPERIMENTAL
Intervention: R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 33
Study: 28978306

Group type: EXPERIMENTAL
Intervention: 4D PET-CT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3D PET-CT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4D CT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4D CT with co-registered 3D PET
Number of subjects: 15
Study: 28978463

Group type: EXPERIMENTAL
Intervention: Limited screening strategy
Number of subjects: 392

Group type: COMPARATOR
Intervention: Limited screening and FDG PET/CT
Number of subjects: 392
Study: 28978527

Group type: EXPERIMENTAL
Intervention: Basic life support plus advanced life support response
Number of subjects: 5572

Group type: COMPARATOR
Intervention: Emergency medical services only (control)
Number of subjects: 5572
Study: 28978540

Group type: EXPERIMENTAL
Intervention: Functional vitamin B-6 status
Number of subjects: 0
Study: 28978547

Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method
Number of subjects: 0
Study: 28978551

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I testing in patients with renal impairment
Number of subjects: 4726

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I testing in patients without renal impairment
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Patients with renal impairment and elevated cardiac troponin concentrations
Number of subjects: 4726
Study: 28978797

Group type: EXPERIMENTAL
Intervention: Aprepitant 375 mg per day for 28 days
Number of subjects: 12
Study: 28978801

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5,000 IU cholecalciferol daily for 90 days)
Number of subjects: 0
Study: 28979661

Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate Gel 0.015%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28980004

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg infused over 30 minutes every 21 days
Number of subjects: 12
Study: 28980198

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg/day
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) 72 mg/day
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) and OROS-MPH
Number of subjects: 1013
Study: 28980204

Group type: EXPERIMENTAL
Intervention: DFCAT model
Number of subjects: 0
Study: 28980394

Group type: COMPARATOR
Intervention: HDV RNA-positive patients
Number of subjects: 1267
Study: 28980442

Group type: EXPERIMENTAL
Intervention: Hypofractionated prostate radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical tool for determining patient eligibility
Number of subjects: 0
Study: 28980446

Group type: EXPERIMENTAL
Intervention: BIVV009 (60 mg/kg, 4 weekly doses)
Number of subjects: 10
Study: 28980462

Group type: EXPERIMENTAL
Intervention: Ranger paclitaxel-coated balloon angioplasty
Number of subjects: 172
Study: 28980942

Group type: EXPERIMENTAL
Intervention: N + WSH intervention arm
Number of subjects: 662

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 662
Study: 28981385

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study: 28981568

Group type: EXPERIMENTAL
Intervention: ΔPOP (pleth variability index) during pneumoperitoneum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ΔPOP cut-off point of 38%
Number of subjects: 120
Study: 28981994

Group type: EXPERIMENTAL
Intervention: 1% transdermal testosterone gels
Number of subjects: 0
Study: 28982142

Group type: EXPERIMENTAL
Intervention: Vitrification of blastocysts with a ≥ 3 h culture interval (Group IV)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Vitrification of blastocysts with a < 3 h culture interval (Group I)
Number of subjects: 223
Study: 28982159

Group type: EXPERIMENTAL
Intervention: Awareness of hypertension
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 1159
Study: 28982258

Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage combined with a duodenal stent
Number of subjects: 110

Group type: COMPARATOR
Intervention: EUS-guided biliary drainage
Number of subjects: 110

Group type: COMPARATOR
Intervention: Metal stents
Number of subjects: 110
Study: 28982374

Group type: EXPERIMENTAL
Intervention: High malaria burden (≥ 2 episodes of symptomatic malaria or ≥ 50% of samples LAMP+)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Low malaria burden (0-1 episodes of symptomatic malaria and < 50% of samples LAMP+)
Number of subjects: 282

Group type: COMPARATOR
Intervention: No malaria exposure during pregnancy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Detection of placental parasites by any method
Number of subjects: 282
Study: 28982495

Group type: EXPERIMENTAL
Intervention: High-energy breakfast (contributing to >20% of total daily energy intake)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Skipping breakfast (consuming <5% of total daily energy)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Low-energy breakfast (contributing between 5% and 20% of total daily energy intake)
Number of subjects: 4052
Study: 28982667

Group type: EXPERIMENTAL
Intervention: Excretion of endogenous cholesterol
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Reverse cholesterol transport pathway
Number of subjects: 86
Study: 28982765

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28982813

Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Younger patients and men
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Patients viewing health status as dependent on external persons
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Patients viewing health status as determined by chance
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Overall anxiety levels
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 1000
Study: 28982814

Group type: EXPERIMENTAL
Intervention: Emotion regulation group therapy (ERGT)
Number of subjects: 95
Study: 28982834

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: suPAR levels
Number of subjects: 150
Study: 28982839

Group type: EXPERIMENTAL
Intervention: Clinical evaluation subcohort (participants meeting three or more IGD criteria)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Representative subcohort (randomly selected 10% of the iCURE)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 3000
Study: 28983018

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (30 µg/kg every other day for 6 doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (50 µg/kg for 10 doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (40 µg/kg for 10 doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (50 µg/kg × 6 doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 55
Study: 28983166

Group type: EXPERIMENTAL
Intervention: Saudi nationals (SA nationals)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Expatriates
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 550
Study: 28983800

Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at GPS-upstream domain
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at transmembrane domain
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PKD1 non-truncating-type mutations at cytoplasmic C-terminal tail (CTT) domain
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PKD1 truncating-type mutations
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PKD1 3'-region truncating-type mutations
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PKD1 3'-region non-truncating-type mutations
Number of subjects: 410
Study: 28983926

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 2884
Study: 28984053

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 0
Study: 28984179

Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: IM interferon beta-1a
Number of subjects: 0
Study: 28984517

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) - either intensity modulated (IMRT) or 3D conformal (3DCRT), 54 Gy in 30 fractions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historical control (GTR alone)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historical control (GTR + RT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 52
Study: 28984909

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 3693

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3693
Study: 28985241

Group type: EXPERIMENTAL
Intervention: High-Salt (HS) diet (18.0 g/day NaCl)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-Salt (LS) diet (3.0 g/day NaCl)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-Salt + K+ (HS + K+) diet (18.0 g/day NaCl and 4.5 g/day KCl)
Number of subjects: 42
Study: 28985589

Group type: EXPERIMENTAL
Intervention: Bi-factor PHQ-ADS model
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: PHQ-ADS
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 182
Study: 28986165

Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for glutamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for tau-methylhistidine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for arginine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole body production (WBP) for β-Hydroxy β-Methylbutyrate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clearance of arginine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clearance of glutamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clearance of leucine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clearance of KIC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Peak leg extension force
Number of subjects: 27
Study: 28986266

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) with methylene blue 0.1%; n = 24
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Narrow-band Imaging (NBI); n = 26
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Narrow-band Imaging (NBI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High confidence diagnosis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Assessment of pit pattern I or II
Number of subjects: 27
Study: 28986337

Group type: EXPERIMENTAL
Intervention: Neuromuscular monitoring e-learning module
Number of subjects: 10000
Study: 28986407

Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI (ferumoxytol, 4 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: USPIO-enhanced MRI
Number of subjects: 14
Study: 28986415

Group type: EXPERIMENTAL
Intervention: Asleep DBS
Number of subjects: 69

Group type: COMPARATOR
Intervention: Awake DBS
Number of subjects: 69
Study: 28986471

Group type: EXPERIMENTAL
Intervention: AVICH score
Number of subjects: 325

Group type: COMPARATOR
Intervention: ICH score
Number of subjects: 325

Group type: COMPARATOR
Intervention: sSM grade
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Modified Rankin score (mRS)
Number of subjects: 325
Study: 28986467

Group type: EXPERIMENTAL
Intervention: MDS-UPDRS Part I score in PD subjects
Number of subjects: 423

Group type: COMPARATOR
Intervention: MDS-UPDRS Part I score in HC
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Longitudinal increase in NMS severity
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Higher baseline NMS score
Number of subjects: 423
Study: 28986504

Group type: EXPERIMENTAL
Intervention: Sitagliptin (part of the TECOS trial)
Number of subjects: 1084
Study: 28986852

Group type: EXPERIMENTAL
Intervention: PC-CMV (fully synchronized pressure-controlled ventilation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PC-SIMV (partially synchronized pressure-controlled ventilation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: PC-IMV (non-synchronized pressure-controlled ventilation using airway pressure release ventilation)
Number of subjects: 13
Study: 28986931

Group type: EXPERIMENTAL
Intervention: Change in VTI after 45° passive leg raising
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardised anaesthesia, intravenous coloading, and prophylactic vasopressor treatment
Number of subjects: 40